CA102 / Curigin - LARVOL DELTA

Chong Kun Dang signs licensing deal for Curigin's bladder cancer gene therapy (Korea Biomedical Review) - "Chong Kun Dang said it has entered into a licensing agreement with Curigin, a local gene therapy developer, for the latter's CA102, a gene therapy candidate targeting superficial bladder cancer....The partnership grants Chong Kun Dang exclusive global rights to CA102."

Licensing / partnership • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy (Businesswire) - "Charles River Laboratories International, Inc...announced a collaboration for adenoviral vector production. The gene therapy developer will leverage Charles River's market-leading expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials....Based on preclinical evaluation data for CA102, Curigin expects to submit an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) within the year."

IND • Licensing / partnership • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor